Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2005-09-20
2005-09-20
Winkler, Ulrike (Department: 1648)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C435S005000
Reexamination Certificate
active
06946125
ABSTRACT:
The present invention provides methods of preventing or treating West Nile virus as well as infections caused by other viruses of the Flaviviridae family in animals comprising administering to the animal an effective amount of ribavirin and/or interferon alpha-2b.
REFERENCES:
patent: 6387365 (2002-05-01), Albrecht et al.
patent: WO 96/36351 (1996-11-01), None
Merimsky et al. Neurotoxicity of interferon-alpha. Anticancer Drugs (1992) vol. 3, No. 6, 567-570.
Gokcil et al. Alpha-interferon and isoprinosine in adult-onset subacute sclerosing panencephalitis. Journal of Neurological Science (1999) vol. 162, No. 1, pp. 62-64.
Takahashi et al. The cooperative effect of interferon-alpha and ribavirin on subacute sclerosing panencephalitis (SSPE) virus infections, in vitro and in vivo. Antiviral Research (1998) vol. 37, No. 1, pp. 29-35.
Crance et al. Antiviral substances inhibiting in vitro replication of several arboviruses (Bunyaviridae, Flaviviridae, Togaviridae. Travaux Scientifiques des Chercheurs du Service de Sante des Armees (1996) vol. 0, No. 17, pp. 57-58. (abstract only).
Crance et al. Selection of antiviral compounds active on several Flaviviruses: Clinical perspectives.
Travaux Scientifiques des Chercheurs du Service de Sante des Armees. vol. No. 20, pp. 35-36 (1999) and English translation thereof.
Leyseen et al., “Perspectives for the Treatment of Infections with Flaviviridac”, Clinical Microbiology Reviews, vol. No. 13, No. 1, pp. 67-82 (2000).
Written Opinion for PCT/US01/26301.
International Search Report for PCT/US01/26301.
Enserink, “West Nile Drugs, Vaccine Still Years Away”, Science vol. No. 290 No. 5496, p. 1483 (2000).
Hirsch et al., Nucleoside derivatives and interferons as antiviral agents, Current Clinical Topics in Infectious Disease., vol. 3:30-53 (1981).
Roberts et al., Phase I Clinical Studies of Ribavirin in High Risk Patients for the Acquired Immunodeficiency Syndrome, Academic. Press p. 95-112.
Holmes et al., Lassa Fever in the United States, The New England Journal of Medicine, pp. 1120-1123 (1990).
Odelola, Herbert, Antiviral Activity of Virazole on Replication of Viruses Isolated in Nigeria, Virology, pp. 334-335 (1977).
Update: West Nile Virus Encephalitis-New York, 1999, MMWR 48:944-955.
Guidelines for Surveillance, Prevention, and Control of West Nile Virus Infection-United States, MMWR, 49:2 p. 25-28 (2000).
Update: West Nile Virus Activity-Northeastern United States, MMWR, 49:31 p. 714-718 (2000).
Human West Nile Virus Surveillance-Connecticut, New Jersey, and New York, MMWR, 50:14 p. 265-268 (2000).
Laskin et al., Ribavirin Disposition in High Risk Patients for Acquired Immunodeficiency Syndrome, Clinical Pharmacology And Therapeutics, vol. 41, No. 5 pp. 546-555 (1987).
Roberts et al., Ribavirin Pharmacodynamics in High-Risk Patients for Acquired Immunodeficiency Syndrome, Clinical Pharmacology and Therapeutics, vol. 42, No. 4 pp. 365-373 (1987).
Hosoya et al., High-Dose Intravenous Ribavirin Therapy for Subacute Sclerosing Panencephalitis, Antimicrobial Agents and Chemotherapy, vol. 45, No. 3 pp. 943-945 (2001).
Briese et al., Testing for West Nile Virus, The Lancet, vol. 356:1110 (2000).
Wang et al., Effect of Dosing Selection on Pharmocokinetics of Alpha Interferon and Anti-Alpha Interferon Neutralizing Antibody in Mice, Chronopharmacology of IFN-a, vol. 45:176-180 (2001).
Barry et al., Arenavirus Infection-Connecticut, MMWR, vol. 43 No. 34 pp. 635-636 (1994).
Forni et al., Severe Measles Pneumonitis in Adults: Evaluation of Clinical Characteristics and Therapy with Intravenous Ribavirin, Clinical Infectious Diseases, Vo. 19:454-462 (1994).
Hoch et al., Crimean Congo-Haemorrhagic Fever treated with oral ribavirin, The Lancet, vol. 346:472-476 (1995).
Barry et al., Brief Report: Treatment of a Laboratory-Acquired Sabia Virus Infection, The New England Journal of Medicine, vol. 333:294-318 (1995).
Merigan, Thomas C., Interferon-The First Quarter Century, JAMA, vol. 248 No. 19 pp. 2513-2516 (1982).
Hayden, Fred, Basic Principles in the Diagnosis and Management of Infectious Diseases, Chapter 36 pp. 474-479 (2000).
Smith et al., Distribution of alpha interferon in serum and cerebrospinal fluid after systematic administration, Clin. Pharm. Ther., 37(1):85-88 (1985), Abstract only.
Centers for Disease Control and Prevention. Update: West Nile Virus Activity-Northeastern U.S., MMWR, vol. 284 No. 10 1236-1238 (2000).
Centers for Disease Control and Prevention. Surveillance for West Nile Virus in Overwintering Mosquitoes-New York, vol. 238 No. 18 pp. 2380-2382 (2000).
Centers for Disease Control and Prevention. Update: West Nile Virus Activity-Northeastern United States, vol. 284 No. 13 pp. 1643-1644 (2000).
Centers for Disease Control and Prevention. Update: West Nile Virus Activity-Eastern U.S., vol. 284 No. 24 pp. 3119-3120 (2000).
Briese et al., Detection of West Nile virus sequences in cerebrospinal fluid, The Lancet, vol. 355:1614-1616 (2000).
Briese et al., Identification of a Kunjin/West Nile-like flavivirus in brains of patients with New York encephalitis, The Lancet, vol. 354:1261-1262 (1999).
Kesson et al., Progressive Vaccinia Treated with Ribavirin and Vaccinia Immune Globulin, Clinical Infectious Disease, vol. 25:911-914 (1997).
Ljungman et al., Oral Ribavirin for Prevention of Severe Liver Disease Caused by Hepatitis C Virus During Allogeneic Bone Marrow Transplantation, Clinical Infectious Disease, vol. 23:167-169 (1996).
Japour et al., A Phase-I Study of the Safety, Pharmacokinetics, and Antiviral Activity of Combination Didanosine and Ribavirin in Patients with HIV-1 Disease, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 13:235-246 (1996).
Huggins et al., Prospective, Double-Blind, Concurrent, Placebo-Controlled Clinical Trial of Intravenous Ribavirin Therapy of Hemorrhagic Fever with Renal Syndrome, The Journal of Infectious Disease, vol. 164:1119-1127 (1991).
Paul Glue, M.D., The Clinical Pharmacology of Ribavirin, Seminars in Liver Disease, 19:17-24 (1999).
N. Raphael Shulman, Assessment of Hematologic Effects of Ribavirin in Humans, Academic Press., 94:29251-29264 (1984).
Centers for Disease Control and Prevention. West Nile Virus Activity-New York and New Jersey, vol. 284 No. 7 pp. 823-824 (2000).
Sidwell, R.W. et al., Ribavirin: An antiviral Agent, Pharmacol. Ther., vol. 6 pp. 2928529308, (1979).
Phochoda et al., Hantavirus-Associated Acute Respiratory Failure, The New England Journal of Medicine, pp. 1744 (1993).
Centers for Disease Control and Prevention. Guidelines for Surveillance, Prevention, and Control of West Nile Virus Infection-U.S. vol. 49 No. 2 pp. 25-28 (2000).
Holmes et al., Lassa Fever in the United States, The New England Journal of Medicine, 323:11201123 (1990).
Cardiovascular Infection by Chlamydia pneumonia Is Not Related to Apolipoprotein E Genotype, Clinic of Infectious Disease 2000;31:1515-1516.
Ishii et al., Effective Ribavirin Concentration in Hamster Brains for Antiviral Chemotherapy for Subactue Sclerosing Panencephalitis, Antimicrobial Agents and Chemotherapy, vol. 40 No. 1 pp. 241-243 (1996).
Sidwell, R.W., Ribavirin: In Vitro Antiviral Activity, Academ. Press., vol. 94 pp. 29265-29284 (1980).
Maslo et al., Ribavirin Therapy for Adenovirus Pneumonia in an AIDS Patient, Amer. Journal Respir. Crit. Care Med., vol. 156:1263-1264 (1997).
Lewisohn et al., Phase I Study of Intravenous Ribavirin Treatment of Respiratory Syncytial Virus Pneumonia after Marrow Transplantation, Antimicrobial Agents and Chemotherapy, vol. 40 No. 11 p. 2555-2557 (1996).
CID: Reassessment of the Indications for Ribavirin Therapy in Respiratory Syncytial Virus Infections, Pediatrics vol. 97 No. 1 pp. 137-140 (1996).
Bisceglie et al., Ribavirin as Therapy for Chronic Hepatitis C, American College of Physicians, vol. 123 No. 12 p. 897-902 (1995).
The Ribavirin ARC Study Group, Multicenter Clinical Trial of Oral Ribavirin in Symptomatic HIV-Infected Patients, Journal of Acquired Immune Deficiency Syndrome, vol. 6 No. 1 pp. 32-41 (1993).
Going et al., Ribavirin for Syncytial G
Kalow & Springut LLP
Schmidt William D.
The New York Hospital Medical Center of Queens
Winkler Ulrike
LandOfFree
Methods of treating West Nile virus infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating West Nile virus infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating West Nile virus infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3387595